Little of substance today. The sweep found no new safety communications, recalls or guideline releases relevant to infectious diseases. Two regulatory items appeared, both from August: a generic fidaxomicin approval on 13 August, and a supplemental approval for an existing product on 18 August.
The fidaxomicin generic is the one worth noting. Fidaxomicin outperforms vancomycin on recurrence in Clostridioides difficile infection and has been in guidelines as a preferred agent for years, but price has kept it a theoretical option in most of the world. Generic entry does not by itself make a drug affordable, and the first generic rarely moves price far. But it starts the process, and it is worth checking whether your formulary committee has looked at fidaxomicin recently — the calculation that excluded it may have been done at the old price.
That is the whole of it. A quiet regulatory day reported as quiet is more useful than a manufactured item, and nothing else in the sweep changes prescribing. The substantive documents for this desk today are the trials above, not the regulators.
- No new safety communications, recalls or guideline releases for infectious diseases today.
- A generic fidaxomicin has been approved; the branded price is no longer the only price.
- Ask your pharmacy to re-cost fidaxomicin if it was excluded from formulary on price grounds.
- Fidaxomicin's advantage over vancomycin is in recurrence, not initial cure — target it accordingly.
- The other item was a supplemental approval to an existing product and changes nothing clinically.
The statistics, in plain English
A generic approval is a regulatory and economic event, not a clinical one: the drug is the same molecule, held to bioequivalence standards, with no new efficacy or safety data attached. Nothing about how fidaxomicin performs has changed. What may change is which patients can be offered it, and that is a formulary question rather than an evidence question.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free